Drawing for Serial No. 79407786

USPTO serial 79407786

Serial No. 79407786

Reviewed by CopyMark Law Group

Reg. 7989014Status 700Registered
Filing date
Status date
Registration date
Oct 21, 2025
Examiner
SPEAKE, WADE E
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with Serial No. 79407786?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Maury M. Tepper, III

Maury M. Tepper, III Tepper & Eyster, PLLC3724 Benson DriveRaleigh, NC 27609United States

Goods and services

ClassDescriptionStatusFirst use
005Anti-infectives for human use; anti-inflammatories for human use; antibacterial pharmaceutical preparations for human use; antibiotics for human use; antifungal preparations for human use; antivirals for human use; cardiovascular pharmaceutical preparations for human use; dermatological pharmaceutical preparations for human use; pharmaceutical preparations for human use for inhaling for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations for human use acting on the central nervous system; pharmaceutical preparations and substances for human use for the prevention and treatment of gastro-intestinal diseases; pharmaceutical preparations for human use for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculoskeletal system and the genitourinary system; pharmaceutical preparations for human use, used in hematology and in tissue and organ transplantation; pharmaceutical preparations for human use for the prevention and treatment of eye diseases; pharmaceutical preparations for human use for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for human use for the prevention and treatment of diseases and disorders related to the immune system; pharmaceutical preparations for human use for the prevention and treatment of kidney diseases; pharmaceutical preparations for human use for the prevention and treatment of diabetes; pharmaceutical preparations for human use for the prevention and treatment of hypertension; pharmaceutical preparations for human use for the prevention and treatment of skin conditions; pharmaceutical preparations for human use, used in dermatology; pharmaceutical preparations for human use, used in urology; pharmaceutical preparations for human use, used in ophthalmology; pharmaceutical preparations for human use for the prevention and treatment of cancer and tumors; pharmaceutical preparations for human use for the prevention and treatment of allergies; pharmaceutical preparations for human use for the prevention and treatment of bone diseases; pharmaceutical preparations for human use for the prevention and treatment of respiratory diseases and asthmaACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 12, 2026NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 14, 2026FINVFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 30, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Apr 30, 2026FIMPFINAL DISPOSITION PROCESSED—
Apr 9, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Mar 23, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 23, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Jan 21, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 21, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Oct 21, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 2, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 2, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 27, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 31, 2025CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 30, 2025TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 30, 2025CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 30, 2025TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 29, 2025RFNTREFUSAL PROCESSED BY IB—
Mar 10, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 10, 2025RFRRREFUSAL PROCESSED BY MPU—
Jan 22, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jan 21, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 10, 2025DOCKASSIGNED TO EXAMINER—
Nov 1, 2024MAFRAPPLICATION FILING RECEIPT MAILED—
Nov 1, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 1, 2024LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Oct 24, 2024REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance